Assessment of Sclerostin and Interleukin 6 Levels and Selected Anthropometric Parameters in Patients Receiving Hemodialysis Replacement Therapy—Pilot Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. The Course of the Study
2.2. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Limitations
Author Contributions
Funding
Conflicts of Interest
References
- Barcellos, F.C.; Santos, I.S.; Umpierre, D.; Bohlke, M.; Hallal, P.C. Effects of exercise in the whole spectrum of chronic kidney disease: A systematic review. Clin. Kidney J. 2015, 8, 753–765. [Google Scholar] [CrossRef] [Green Version]
- Myśliwiec, M.C. Nefrologia. Wyd. 2; Medical Tribune Polska: Warszawa, Poland, 2017. [Google Scholar]
- Renke, M.; Parszuto, J.; Rybacki, M.; Wołyniec, W.; Rutkowski, P.; Rutkowski, B.; Walusiak-Skorupa, J.; Dębska-Ślizień, A. Chronic Kidney Disease–The relevant information for an occupational physician. Med. Pr. 2018, 69, 67–75. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brandenburg, V.M.; D’Haese, P.; Deck, A.; Mekahli, D.; Meijers, B.; Neven, E.; Evenepoel, P. From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD. Pediatr. Nephrol. 2016, 31, 195–206. [Google Scholar] [CrossRef] [PubMed]
- Wang, X.H.; Mitch, W.E. Mechanisms of muscle wasting in chronic kidney disease. Nat. Rev. Nephrol. 2014, 10, 504–516. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Xiong, L.; Jung, J.-U.; Wu, H.; Xia, W.-F.; Pan, J.-X.; Shen, C.; Mei, L.; Xiong, W.C. Lrp4 in osteoblasts suppresses bone formation and promotes osteoclastogenesis and bone resorption. Proc. Natl. Acad. Sci. USA 2015, 112, 3487–3492. [Google Scholar] [CrossRef] [Green Version]
- Bonani, M.; Rodriguez, D.; Fehr, T.; Mohebbi, N.; Brockmann, J.; Blum, M.; Graf, N.; Frey, D.; Wüthrich, R.P. Sclerostin blood levels before and after kidney transplantation. Kidney Blood Press. Res. 2014, 39, 230–239. [Google Scholar] [CrossRef]
- Brown, J.P.; Albert, C.; Nassar, B.A.; Adachi, J.D.; Cole, D.; Davison, K.S.; Dooley, K.C.; Don-Wauchope, A.; Douville, P.; Hanley, D.A.; et al. Bone turnover markers in the management of postmenopausal osteoporosis. Clin. Biochem. 2009, 42, 929–942. [Google Scholar] [CrossRef]
- Desjardins, L.; Liabeuf, S.; Oliveira, R.B.; Louvet, L.; Kamel, S.; Lemke, H.D.; Vanholder, R.; Choukroun, G.; Massy, Z.A.; European Uremic Toxin (EUTox) Work Group. Uremic toxicity and sclerostin in chronic kidney disease patients. Nephrol. Ther. 2014, 10, 463–470. [Google Scholar] [CrossRef]
- Evenepoel, P.; Claes, K.; Viaene, L.; Bammens, B.; Meijers, B.; Naesens, M.; Sprangers, B.; Kuypers, D. Decreased circulating sclerostin levels in renal transplant recipients with persistent hyperparathyroidism. Transplantation 2016, 100, 2188–2193. [Google Scholar] [CrossRef]
- Jean, G.; Chazot, C.; Bresson, E.; Zaoui, E.; Cavalier, E. high serum sclerostin levels are associated with a better outcome in haemodialysis patients. Nephron 2016, 132, 181–190. [Google Scholar] [CrossRef]
- Moysés, R.M.A.; Jamal, S.A.; Graciolli, F.G.; dos Reis, L.M.; Elias, R.M. Can we compare serum sclerostin results obtained with different assays in hemodialysis patients? Int. Urol. Nephrol. 2015, 47, 847–850. [Google Scholar] [CrossRef] [PubMed]
- Wang, J.; Qiu, X.; Xu, T.; Sheng, Z.; Yao, L. Sclerostin/receptor related protein 4 and ginkgo biloba extract alleviates β-glycerophosphate-induced vascular smooth muscle cell calcification by inhibiting Wnt/β-catenin pathway. Blood Purif. 2019, 47, 17–23. [Google Scholar] [CrossRef] [PubMed]
- Buczko, W.; Danysz, A. Kompendium Farmakologii i Farmakoterapii. Wyd.6; Edra Urban&Partner: Wrocław, Poland, 2016; ISBN 978-83-65373-27-4. [Google Scholar]
- Gołąb, J.; Jakóbisiak, M.; Lasek, W.; Stokłosa, T. Immunologia. Wyd.7; Wydawnictwo Naukowe PWN: Warszawa, Poland, 2017; ISBN 9788301194505. [Google Scholar]
- Mutschler, E.; Geisslinger, G.; Kroemer, H.K.; Menzel, S.; Ruth, P.; Droździk, M.; Kocić, I.; Pawlak, D.; Malinowska, B.; Grotthus, B.; et al. Mutschler-farmakologia i toksykologia. Podręcznik; MedPharm Polska: Wrocław, Poland, 2016; ISBN 9788378460374. [Google Scholar]
- Febbraio, M.A.; Ott, P.; Nielsen, H.B.; Steensberg, A.; Keller, C.; Krustrup, P.; Secher, N.H.; Pedersen, B.K. Hepatosplanchnic clearance of interleukin-6 in humans during exercise. Am. J. Physiol. Endocrinol. Metab. 2003, 285, E397–E402. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Czekalski, S.; Pawlaczyk, K.; Oko, A. Rozwój zespołu niedożywienie–zapalenie–miażdżyca (zespół MIA) u chorych z upośledzeniem czynności nerek leczonych zachowawczo. Nefrol. Dial. Pol. 2008, 8, 112–115. [Google Scholar]
- Bernecker, C.; Scherr, J.; Schinner, S.; Braun, S.; Scherbaum, W.A.; Halle, M. Evidence for an exercise induced increase of TNF-α and IL-6 in marathon runners. Scand. J. Med. Sci. Sports 2013, 23, 207–214. [Google Scholar] [CrossRef]
- Isung, J.; Aeinehband, S.; Mobarrez, F.; Nordström, P.; Runeson, B.; Asberg, M.; Piehl, F.; Jokinen, J. High interleukin-6 and impulsivity: determining the role of endophenotypes in attempted suicide. Transl. Psychiatry 2014, 4, e470. [Google Scholar] [CrossRef] [Green Version]
- Brończyk-Puzoń, A.; Koszowska, A.; Bieniek, J. Podstawowe pomiary antropometryczne i pochodne wskaźniki w poradnictwie dietetycznym–część pierwsza. Piel. Zdr. Publ. 2018, 8, 217–222. [Google Scholar] [CrossRef] [Green Version]
- Załuska, W. Dry body weight—old problem, new methods. Forum. Nefrol. 2011, 4, 100–103. [Google Scholar]
- Drozdowski, Z. Antropometria w Wychowaniu Fizycznym. Wyd. 4 zm i Uzup; Akademia Wychowania Fizycznego im. Eugeniusza Piaseckiego w Poznaniu: Poznań, Poland, 1998; ISBN 83-86336-51-X. [Google Scholar]
- WHO World Health Organization. Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation on Obesity; WHO/NUT/NCD/981; WHO: Geneva, Switzerland, 1998. [Google Scholar]
- Burton, J.O.; Gray, L.J.; Webb, D.R.; Davies, M.J.; Khunti, K.; Crasto, W.; Carr, S.J.; Brunskill, N.J. Association of anthropometric obesity measures with chronic kidney disease risk in a non-diabetic patient population. Nephrol. Dial. Transplant. 2012, 27, 1860–1866. [Google Scholar] [CrossRef] [Green Version]
- Ishimura, E.; Okuno, S.; Kim, M.; Yamamoto, T.; Izumotani, T.; Otoshi, T.; Shoji, T.; Inaba, M.; Nishizawa, Y. Increasing body fat mass in the first year of hemodialysis. J. Am. Soc. Nephrol. 2001, 12, 1921–1926. [Google Scholar]
- Pawlak-Buś, K.; Leszczyński, P. Sklerostyna-nowy cel terapii anabolcznej niskiej masy kostnej. Reumatologia 2010, 48, 183–187. [Google Scholar]
- Malluche, H.H.; Davenport, D.L.; Cantor, T.; Monier-Faugere, M.-C. Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis. Clin. J. Am. Soc. Nephrol. 2014, 9, 1254–1262. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Claes, K.J.; Viaene, L.; Heye, S.; Meijers, B.; D’Haese, P.; Evenepoel, P. Another vascular calcification inhibitor? J. Clin. Endocrinol. Metab. 2013, 98, 3221–3228. [Google Scholar] [CrossRef] [PubMed]
- Cejka, D.; Marculescu, R.; Kozakowski, N.; Plischke, M.; Reiter, T.; Gessl, A.; Haas, M. Renal elimination of sclerostin increases with declining kidney function. J. Clin. Endocrinol. Metab. 2014, 99, 248–255. [Google Scholar] [CrossRef]
- Delanaye, P.; Krzesinski, J.M.; Warling, X.; Moonen, M.; Smelten, N.; Médart, L.; Bruyère, O.; Reginster, J.Y.; Pottel, H.; Cavalier, E. Clinical and biological determinants of sclerostin plasma concentration in hemodialysis patients. Nephron Clin. Pract. 2014, 128, 127–134. [Google Scholar] [CrossRef]
- Ishimura, E.; Okuno, S.; Ichii, M.; Norimine, K.; Yamakawa, T.; Shoji, S.; Nishizawa, Y.; Inaba, M. Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients. J. Clin. Endocrinol. Metab. 2014, 99, 4315–4320. [Google Scholar] [CrossRef] [Green Version]
- Kanbay, M.; Siriopol, D.; Saglam, M.; Kurt, Y.G.; Gok, M.; Cetinkaya, H.; Karaman, M.; Unal, H.U.; Oguz, Y.; Sari, S.; et al. Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients. J. Clin. Endocrinol. Metab. 2014, 99, E1854–E1861. [Google Scholar] [CrossRef] [Green Version]
- Nowak, A.; Artunc, F.; Serra, A.L.; Pollock, E.; Krayenbühl, P.A.; Müller, C.; Friedrich, B. Sclerostin quo vadis?-Is this a useful long-term mortality parameter in prevalent hemodialysis patients? Kidney Blood Press. Res. 2015, 40, 266–276. [Google Scholar] [CrossRef]
- Clarke, B.L.; Drake, M.T. Clinical utility of serum sclerostin measurements. BoneKEy Rep. 2013, 2, 361. [Google Scholar] [CrossRef] [Green Version]
- Balcı, M.; Kırkpantur, A.; Turkvatan, A.; Mandıroglu, S.; Ozturk, E.; Afsar, B. Sclerostin as a new key player in arteriovenous fistula calcification. Herz 2015, 40, 289–297. [Google Scholar] [CrossRef]
- Pelletier, S.; Dubourg, L.; Carlier, M.-C.; Hadj-Aissa, A.; Fouque, D. The relation between renal function and serum sclerostin in adult patients with CKD. Clin. J. Am. Soc. Nephrol. 2013, 8, 819–823. [Google Scholar] [CrossRef] [PubMed]
- Sato, M.; Hanafusa, N.; Kawaguchi, H.; Tsuchiya, K.; Nitta, K. A Prospective cohort study showing no association between serum sclerostin level and mortality in maintenance hemodialysis patients. Kidney Blood Press. Res. 2018, 43, 1023–1033. [Google Scholar] [CrossRef] [PubMed]
- Kalem, M.N.; Kalem, Z.; Akgun, N.; Bakırarar, B. The relationship between postmenopausal women’s sclerostin levels and their bone density, age, body mass index, hormonal status, and smoking and consumption of coffee and dairy products. Arch. Gynecol. Obstet. 2017, 295, 785–793. [Google Scholar] [CrossRef] [PubMed]
- Amrein, K.; Amrein, S.; Drexler, C.; Dimai, H.P.; Dobnig, H.; Pfeifer, K.; Tomaschitz, A.; Pieber, T.R.; Fahrleitner-Pammer, A. Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J. Clin. Endocrinol. Metab. 2012, 97, 148–154. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hampson, G.; Edwards, S.; Conroy, S.; Blake, G.M.; Fogelman, I.; Frost, M.L. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women. Bone 2013, 56, 42–47. [Google Scholar] [CrossRef]
- Koos, R.; Brandenburg, V.; Mahnken, A.H.; Schneider, R.; Dohmen, G.; Autschbach, R.; Marx, N.; Kramann, R. Sclerostin as a potential novel biomarker for aortic valve calcification: An in-vivo and ex-vivo study. J. Heart Valve Dis. 2013, 22, 317–325. [Google Scholar]
- Hamada–Ode, K.; Taniguhi, Y.; Shimamura, Y.; Fujimoto, S.; Terada, Y. Serum dickkopf-related protein 1 and sclerostin may predict the progression of chronic kidney disease in Japanese patients. Nephrol. Dial. Transplant. 2019, 34, 1426–1427. [Google Scholar] [CrossRef]
- Lima, J.G.; Nobrega, L.H.C.; Lima, N.N.; Dos Santos, M.C.F.; Baracho, M.d.F.P.; Winzenrieth, R.; Bandeira, F.; Mendes-Aguiar, C.D.O.; Neto, F.P.F.; Ferreira, L.C.; et al. Normal bone density and trabecular bone score, but high serum sclerostin in congenital generalized lipodystrophy. Bone 2017, 101, 21–25. [Google Scholar] [CrossRef]
- Wędrychowicz, A.; Sztefko, K.; Starzyk, J.B. Sclerostin and its association with insulin resistance in children and adolescents. Bone 2019, 120, 232–238. [Google Scholar] [CrossRef]
- Figurek, A.; Spasovski, G. Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease-mineral and bone disorder? Int. Urol. Nephrol. 2018, 50, 1863–1870. [Google Scholar] [CrossRef]
- Figurek, A.; Rroji, M.; Spasovski, G. Sclerostin: A new biomarker of CKD-MBD. Int. Urol. Nephrol. 2019, 1–7. [Google Scholar] [CrossRef] [PubMed]
- Caglar, K.; Peng, Y.; Pupim, L.B.; Flakoll, P.J.; Levenhagen, D.; Hakim, R.M.; Ikizler, T.A. Inflammatory signals associated with hemodialysis. Kidney Int. 2010, 62, 1408–1416. [Google Scholar] [CrossRef] [PubMed]
- Yamamoto, T.; Nascimento, M.M.; Hayashi, S.Y.; Qureshi, A.R.; Waniewski, J.; Brodin, L.Å.; Anderstam, B.; Lind, B.; Riella, M.C.; Seeberger, A.; et al. Changes in circulating biomarkers during a single hemodialysis session. Hemodial. Int. 2013, 17, 59–66. [Google Scholar] [CrossRef] [PubMed]
- Pecoits-Filho, R.; Lindholm, B.; Axelsson, J.; Stenvinkel, P. Update on interleukin-6 and its role in chronic renal failure. Nephrol. Dial. Transplant. 2003, 18, 1042–1045. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bolton, C.H.; Downs, L.G.; Victory, J.G.; Dwight, J.F.; Tomson, C.R.; Mackness, M.I.; Pinkney, J.H. Endothelial dysfunction in chronic renal failure: Roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol. Dial. Transplant. 2001, 16, 1189–1197. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dungey, M.; Young, H.M.L.; Churchward, D.R.; Burton, J.O.; Smith, A.C.; Bishop, N.C. Regular exercise during haemodialysis promotes an anti-inflammatory leucocyte profile. Clin. Kidney J. 2017, 10, 813–821. [Google Scholar] [CrossRef] [PubMed]
- Kimmel, P.L.; Phillips, T.M.; Simmens, S.J.; Peterson, R.A.; Weihs, K.L.; Alleyne, S.; Cruz, I.; Yanovski, J.A.; Veis, J.H. Immunologic function and survival in hemodialysis patients. Kidney Int. 1998, 54, 236–244. [Google Scholar] [CrossRef] [Green Version]
- Pecoits-Filho, R.; Bárány, P.; Lindholm, B.; Heimbürger, O.; Stenvinkel, P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol. Dial. Transplant. 2002, 17, 1684–1688. [Google Scholar] [CrossRef]
- Pupim, L.B.; Himmelfarb, J.; McMonagle, E.; Shyr, Y.; Ikizler, T.A. Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. Kidney Int. 2004, 65, 2371–2379. [Google Scholar] [CrossRef] [Green Version]
- Goldstein, S.L.; Currier, H.; Watters, L.; Hempe, J.M.; Sheth, R.D.; Silverstein, D. Acute and chronic inflammation in pediatric patients receiving hemodialysis. J. Pediatr. 2003, 143, 653–657. [Google Scholar] [CrossRef]
- Kato, A.; Odamaki, M.; Takita, T.; Maruyama, Y.; Kumagai, H.; Hishida, A. Association between interleukin-6 and carotid atherosclerosis in hemodialysis patients. Kidney Int. 2002, 61, 1143–1152. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wanic-Kossowska, M.; Pawliczak, E. Stężenie w surowicy wybranych cytokin prozapalnych. Now. Lek. 2012, 81, 605–610. [Google Scholar]
- Maes, M.; Bosmans, E.; De Jongh, R.; Kenis, G.; Vandoolaeghe, E.; Neels, H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997, 9, 853–858. [Google Scholar] [CrossRef] [PubMed]
- Maes, M.; Meltzer, H.Y.; Bosmans, E.; Bergmans, R.; Vandoolaeghe, E.; Ranjan, R.; Desnyder, R. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J. Affect. Disord. 1995, 34, 301–309. [Google Scholar] [CrossRef]
- Nawrocka, M. Ocena Stężenia Wybranych Interleukin i Parametrów Funkcji Nerek u Chorych z Zespołem Metabolicznym. Ph.D. Thesis, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Wydział Lekarski I, Poznań, Poland, 2015. [Google Scholar]
- Roytblat, L.; Rachinsky, M.; Fisher, A.; Greemberg, L.; Shapira, Y.; Douvdevani, A.; Gelman, S. Raised interleukin-6 levels in obese patients. Obes. Res. 2000, 8, 673–675. [Google Scholar] [CrossRef]
- Park, H.S.; Park, J.Y.; Yu, R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res. Clin. Pract. 2005, 69, 29–35. [Google Scholar] [CrossRef]
- Wei, J.; Xu, H.; Davies, J.L.; Hemmings, G.P. Increase of plasma IL-6 concentration with age in healthy subjects. Life Sci. 1992, 51, 1953–1956. [Google Scholar] [CrossRef]
- Kamimura, M.A.; Draibe, S.A.; Dalboni, M.A.; Cendoroglo, M.; Avesani, C.M.; Manfredi, S.R.; Canziani, M.E.F.; Cuppari, L. Serum and cellular interleukin-6 in haemodialysis patients: Relationship with energy expenditure. Nephrol. Dial. Transplant. 2007, 22, 839–844. [Google Scholar] [CrossRef] [Green Version]
Parameter | Study Group (n = 34) | Control Group (n = 31) | p-Value | ||||
---|---|---|---|---|---|---|---|
X (SD) | Range | Me | X (SD) | Range | Me | ||
Age [years] | 59.8 (9.8) | 29.0–78.0 | 60.5 | 55.4 (9.37) | 35.0–73.0 | 59.0 | 0.1269 |
Body weight [kg] | 74.6 (14.5) | 64.5–81.5 | 75.4 | 78.0 (16.03) | 65.8–91.3 | 79.0 | 0.45012 |
BMI [kg/m2] | 25.8 (4.4) | 22.1–28.8 | 25.3 | 26.7 (4.1) | 24.1–29.8 | 25.9 | 0.33432 |
Waist circumference [cm] | 96.8 (14.7) | 88–105 | 96.5 | 91.4 (16.3) | 83–100 | 89.0 | 0.06752 |
Hip circumference [cm] | 101.7 (10.5) | 73.0–123.0 | 102.0 | 102.5 (7.5) | 91.0–120.2 | 103.0 | 0.8541 |
WHR | 0.9 (0.1) | 0.7–1.1 | 0.9 | 0.8 (0.1) | 0.7–1.1 | 0.9 | 0.0108 * |
Hospitalizations | 2.9 (2.7) | 0.0–15.0 | 2.5 | 0.2 (0.5) | 0.0–3.0 | 0.0 | 0.00012 * |
Variable | Observation Period | Study Group (n = 34) | Control Group (n = 31) | p-Value | ||||
---|---|---|---|---|---|---|---|---|
X (SD) | Range | Me | X (SD) | Range | Me | |||
Sclerostin [pg/mL] | E0 | 548.1 (382.2) | 155.9–1735.4 | 472.8 | 391.8 (94.4) | 243.9–597.7 | 365.4 | 0.2170 |
E3 | 432.4 (282.9) | 148.0–1553.4 | 387.4 | 404.8 (104.5) | 232.1–619.4 | 411.2 | 0.5501 | |
E6 | 415.0 (208.5) | 147.8–1032.4 | 396.5 | 392.1 (85.2) | 249.0–567.6 | 388.0 | 0.9581 | |
Interleukin 6 [pg/mL] | E0 | 9.0 (12.8) | 1.2–56.8 | 4.2 | 2.7 (7.7) | 0.2–43.9 | 1.0 | 0.0000 * |
E3 | 10.4 (5.9) | 1.2–68.4 | 4.8 | 2.2 (5.6) | 0.1–32.1 | 1.2 | 0.0000 * | |
E6 | 9.0 (12.3) | 1.1–51.6 | 5.2 | 2.4 (6.7) | 0.3–38.3 | 1.1 | 0.0000 * |
Parameter | Sclerostin | Interleukin 6 | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Study Group (n = 34) | Control Group (n = 31) | Study Group (n = 34) | Control Group (n = 31) | ||||||||||
E0 | E3 | E6 | E0 | E3 | E6 | E0 | E3 | E6 | E0 | E3 | E6 | ||
Body weight [kg] | R | −0.10 | −0.07 | −0.01 | 0.26 | 0.36 | 0.26 | 0.03 | 0.05 | 0.03 | 0.25 | 0.36 | 0.49 |
p-value | 0.5723 | 0.6637 | 0.9781 | 0.1564 | 0.0443 * | 0.1544 | 0.8529 | 0.7546 | 0.8651 | 0.1687 | 0.0480 * | 0.0043 * | |
BMI [kg/m2] | R | −0.14 | −0.16 | −0.13 | 0.27 | 0.43 | 0.29 | −0.06 | −0.06 | −0.07 | 0.33 | 0.46 | 0.53 |
p-value | 0.4560 | 0.3478 | 0.4774 | 0.1279 | 0.0156 * | 0.1168 | 0.7254 | 0.7281 | 0.6745 | 0.0689 | 0.0097 * | 0.0021 * | |
Waist circumference [cm] | R | −0.20 | −0.07 | −0.10 | 0.45 | 0.49 | 0.44 | 0.12 | 0.08 | 0.11 | 0.27 | 0.54 | 0.50 |
p-value | 0.2652 | 0.6856 | 0.5637 | 0.0106 * | 0.0049 * | 0.0112* | 0.4949 | 0.6131 | 0.5452 | 0.1362 | 0.0016 * | 0.0039 * | |
Hip circumference [cm] | R | −0.29 | −0.27 | −0.19 | 0.21 | 0.35 | 0.26 | −0.03 | −0.12 | −0.17 | 0.24 | 0.52 | 0.41 |
p-value | 0.0854 | 0.1178 | 0.2789 | 0.2571 | 0.0522 | 0.1500 | 0.8546 | 0.4753 | 0.3331 | 0.1800 | 0.0025 * | 0.0188 * | |
WHR | R | 0.09 | 0.18 | 0.03 | 0.53 | 0.52 | 0.47 | 0.20 | 0.16 | 0.32 | 0.25 | 0.45 | 0.42 |
p-value | 0.960 | 0.2843 | 0.8442 | 0.0018 * | 0.0026 * | 0.0068 * | 0.2526 | 0.3380 | 0.0574 | 0.1678 | 0.0099 * | 0.0165 * |
Parameter | Sclerostin | Interleukin 6 | |||
---|---|---|---|---|---|
Study Group (n = 34) | Control Group (n = 31) | Study Group (n = 34) | Control Group (n = 32) | ||
E0 | R | 0.14 | 0.34 | 0.08 | 0.46 |
p-value | 0.4018 | 0.0588 | 0.6570 | 0.0101 * | |
E3 | R | 0.53 | 0.48 | 0.02 | 0.52 |
p-value | 0.014 * | 0.0058 * | 0.9281 | 0.0026 * | |
E6 | R | 0.27 | 0.30 | 0.16 | 0.41 |
p-value | 0.1272 | 0.0915 | 0.3412 | 0.0205 * |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Turon-Skrzypinska, A.; Dutkiewicz, G.; Marchelek-Mysliwiec, M.; Dziedziejko, V.; Ciechanowski, K.; Ryl, A.; Rotter, I. Assessment of Sclerostin and Interleukin 6 Levels and Selected Anthropometric Parameters in Patients Receiving Hemodialysis Replacement Therapy—Pilot Study. Medicina 2019, 55, 784. https://doi.org/10.3390/medicina55120784
Turon-Skrzypinska A, Dutkiewicz G, Marchelek-Mysliwiec M, Dziedziejko V, Ciechanowski K, Ryl A, Rotter I. Assessment of Sclerostin and Interleukin 6 Levels and Selected Anthropometric Parameters in Patients Receiving Hemodialysis Replacement Therapy—Pilot Study. Medicina. 2019; 55(12):784. https://doi.org/10.3390/medicina55120784
Chicago/Turabian StyleTuron-Skrzypinska, Agnieszka, Grazyna Dutkiewicz, Malgorzata Marchelek-Mysliwiec, Violetta Dziedziejko, Kazimierz Ciechanowski, Aleksandra Ryl, and Iwona Rotter. 2019. "Assessment of Sclerostin and Interleukin 6 Levels and Selected Anthropometric Parameters in Patients Receiving Hemodialysis Replacement Therapy—Pilot Study" Medicina 55, no. 12: 784. https://doi.org/10.3390/medicina55120784